Evidence map›Paper›PMID 30706376›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2019

Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Courtney J Pokrzywa, Daniel E Abbott, Kristina A Matkowskyj, Sean M Ronnekleiv-Kelly, Emily R Winslow, Sharon M Weber, Alexander V Fisher

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Courtney J PokrzywaDepartment of Surgery, Columbia University Medical Center, New York, NY, USA.
Daniel E AbbottDepartment of Surgery, University of Wisconsin, 600 Highland Avenue, H4/710 Clinical Science Center, Madison, WI, 53792-3284, USA.
Kristina A MatkowskyjDepartment of Pathology, University of Wisconsin, Madison, WI, USA.
Sean M Ronnekleiv-KellyDepartment of Surgery, University of Wisconsin, 600 Highland Avenue, H4/710 Clinical Science Center, Madison, WI, 53792-3284, USA.
Emily R WinslowDepartment of Surgery, University of Wisconsin, 600 Highland Avenue, H4/710 Clinical Science Center, Madison, WI, 53792-3284, USA.
Sharon M WeberDepartment of Surgery, University of Wisconsin, 600 Highland Avenue, H4/710 Clinical Science Center, Madison, WI, 53792-3284, USA.
Alexander V FisherDepartment of Surgery, University of Wisconsin, 600 Highland Avenue, H4/710 Clinical Science Center, Madison, WI, 53792-3284, USA. afisher2@uwhealth.org.ORCID 0000-0002-6531-6861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, many other histologic forms of pancreatic cancer are also recognized. These histologic variants portray unique characteristics in terms of patient demographics, tumor behavior, survival, and responsiveness to treatments. MATERIALS AND

methodsPatients who underwent surgical resection of the pancreas for non-metastatic, invasive pancreatic cancer between 2004 and 2014 were selected from the National Cancer Data Base and categorized by histologic variant according to WHO classification guidelines. Patient demographics, tumor variables, treatment characteristics, and survival were compared between histologic groups and subgroups.

resultsA total of 57,804 patients met inclusion and exclusion criteria and were grouped into eight major histologic categories. Survival analysis by the histologic group showed median overall survival of 20.2 months for ductal adenocarcinoma, 20.5 months for squamous cell carcinoma, 26.8 months for mixed acinar-neuroendocrine carcinomas, 52.6 months for cystic mucinous neoplasms with an associated invasive carcinoma, 67.5 months for acinar cell carcinoma, and 69.3 months for mesenchymal tumors. Median survival was not reached for neuroendocrine tumors and solid-pseudopapillary neoplasms, with 5-year overall survival rates of 84% and 97% respectively.

conclusionsRare subtypes of pancreatic cancer present unique clinicopathologic characteristics and display distinct tumor biologies. This study presents data on demographic, prognostic, treatment, and survival outcomes between rare forms of pancreatic neoplasms in order to aid understanding of the natural history and behavior of these neoplasms, with the hope of serving as a reference in clinical decision-making and ability to provide accurate prognostic information to patients.

Indexed as

Adenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoma, Acinar CellCarcinoma, Pancreatic DuctalCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousNeoplasm StagingNeuroendocrine TumorsPancreatic Intraductal NeoplasmsMucinous neoplasmsNeuroendocrine tumorsPancreatic adenocarcinomaPancreatic cancer subtypes

Identifiers

PMID30706376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.